CD19 and systemic lupus erythematosus: Remarkably, initial clinical trials in humans have demonstrated that in patients with severe SLE refractory to conventional treatments, anti-CD19 CAR T cells were able to achieve complete remission in all 5 patients within 3 months of treatment, and these patients continue to be seronegative for autoantibodies and without symptoms for months after B cells repopulated (296).